Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Capital Expenditures (2020 - 2025)

Benitec Biopharma's Capital Expenditures history spans 5 years, with the latest figure at $6000.0 for Q1 2025.

  • For Q1 2025, Capital Expenditures changed N/A year-over-year to $6000.0; the TTM value through Mar 2025 reached $20000.0, changed N/A, while the annual FY2024 figure was $179000.0, 17800.0% up from the prior year.
  • Capital Expenditures for Q1 2025 was $6000.0 at Benitec Biopharma, up from $1000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $15000.0 in Q1 2021 and bottomed at -$141000.0 in Q2 2021.
  • The 4-year median for Capital Expenditures is $6000.0 (2025), against an average of -$21200.0.
  • The largest annual shift saw Capital Expenditures plummeted 1184.62% in 2021 before it surged 109.22% in 2022.
  • A 4-year view of Capital Expenditures shows it stood at -$141000.0 in 2021, then soared by 109.22% to $13000.0 in 2022, then crashed by 92.31% to $1000.0 in 2023, then surged by 500.0% to $6000.0 in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Capital Expenditures are $6000.0 (Q1 2025), $1000.0 (Q2 2023), and $13000.0 (Q2 2022).